121 related articles for article (PubMed ID: 14705183)
1. Stability of PEGylated salmon calcitonin in nasal mucosa.
Na DH; Youn YS; Park EJ; Lee JM; Cho OR; Lee KR; Lee SD; Yoo SD; DeLuca PP; Lee KC
J Pharm Sci; 2004 Feb; 93(2):256-61. PubMed ID: 14705183
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix assisted laser desorption ionization mass spectrometry (MALDI).
Lang SR; Staudenmann W; James P; Manz HJ; Kessler R; Galli B; Moser HP; Rummelt A; Merkle HP
Pharm Res; 1996 Nov; 13(11):1679-85. PubMed ID: 8956334
[TBL] [Abstract][Full Text] [Related]
3. Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol.
Shin BS; Jung JH; Lee KC; Yoo SD
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):957-60. PubMed ID: 15304989
[TBL] [Abstract][Full Text] [Related]
4. Degradation of salmon calcitonin in rat kidney and liver homogenates.
Liao S; Zhang ZQ; Ruan JX; Qi JK; Liu KL
Pharmazie; 2008 Oct; 63(10):743-7. PubMed ID: 18972837
[TBL] [Abstract][Full Text] [Related]
5. High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation.
Youn YS; Na DH; Lee KC
J Control Release; 2007 Feb; 117(3):371-9. PubMed ID: 17207880
[TBL] [Abstract][Full Text] [Related]
6. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins.
Lee KC; Moon SC; Park MO; Lee JT; Na DH; Yoo SD; Lee HS; DeLuca PP
Pharm Res; 1999 Jun; 16(6):813-8. PubMed ID: 10397599
[TBL] [Abstract][Full Text] [Related]
7. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats.
Lee KC; Park MO; Na DH; Youn YS; Lee SD; Yoo SD; Lee HS; DeLuca PP
Calcif Tissue Int; 2003 Dec; 73(6):545-9. PubMed ID: 14508623
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and biodistribution studies of (125)I-radioiodinated di-PEGylated bone targeting salmon calcitonin analogue in healthy rats.
Yang Y; Bhandari KH; Panahifar A; Doschak MR
Pharm Res; 2014 May; 31(5):1146-57. PubMed ID: 24357414
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol.
Cheng W; Lim LY
J Pharm Sci; 2009 Apr; 98(4):1438-51. PubMed ID: 18704953
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
Bhandari KH; Newa M; Chapman J; Doschak MR
J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins.
Lee KC; Tak KK; Park MO; Lee JT; Woo BH; Yoo SD; Lee HS; DeLuca PP
Pharm Dev Technol; 1999 May; 4(2):269-75. PubMed ID: 10231888
[TBL] [Abstract][Full Text] [Related]
12. Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry.
Na DH; Park MO; Choi SY; Kim YS; Lee SS; Yoo SD; Lee HS; Lee KC
J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):259-63. PubMed ID: 11318423
[TBL] [Abstract][Full Text] [Related]
13. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection.
Youn YS; Kwon MJ; Na DH; Chae SY; Lee S; Lee KC
J Control Release; 2008 Jan; 125(1):68-75. PubMed ID: 18023905
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety.
Cheng W; Lim LY
J Pharm Pharmacol; 2010 Mar; 62(3):296-304. PubMed ID: 20487211
[TBL] [Abstract][Full Text] [Related]
15. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy.
Youn YS; Jung JY; Oh SH; Yoo SD; Lee KC
J Control Release; 2006 Sep; 114(3):334-42. PubMed ID: 16884808
[TBL] [Abstract][Full Text] [Related]
16. PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights.
Ryan SM; Frías JM; Wang X; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2011 Jan; 149(2):126-32. PubMed ID: 20946924
[TBL] [Abstract][Full Text] [Related]
17. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins.
Sinswat P; Tengamnuay P
Int J Pharm; 2003 May; 257(1-2):15-22. PubMed ID: 12711157
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate.
Ryan SM; Wang X; Mantovani G; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2009 Apr; 135(1):51-9. PubMed ID: 19168100
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery.
Tewes F; Gobbo OL; Amaro MI; Tajber L; Corrigan OI; Ehrhardt C; Healy AM
Mol Pharm; 2011 Oct; 8(5):1887-98. PubMed ID: 21882837
[TBL] [Abstract][Full Text] [Related]
20. Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes.
Cho W; Kim MS; Jung MS; Park J; Cha KH; Kim JS; Park HJ; Alhalaweh A; Velaga SP; Hwang SJ
Int J Pharm; 2015 Jan; 478(1):288-296. PubMed ID: 25445994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
